- Home
- JAGX vs MYNZ Comparison
JAGX vs MYNZ Comparison
Compare JAGX & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- MYNZ
- Stock Information
- Founded
- JAGX 2013
- MYNZ 2021
- Country
- JAGX United States
- MYNZ Germany
- Employees
- JAGX N/A
- MYNZ N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- JAGX Health Care
- MYNZ Health Care
- Exchange
- JAGX Nasdaq
- MYNZ Nasdaq
- Market Cap
- JAGX 11.3M
- MYNZ 11.2M
- IPO Year
- JAGX N/A
- MYNZ 2021
- Fundamental
- Price
- JAGX $0.86
- MYNZ $3.78
- Analyst Decision
- JAGX
- MYNZ Hold
- Analyst Count
- JAGX 0
- MYNZ 2
- Target Price
- JAGX N/A
- MYNZ N/A
- AVG Volume (30 Days)
- JAGX 505.4K
- MYNZ 128.8K
- Earning Date
- JAGX 11-13-2024
- MYNZ 10-21-2024
- Dividend Yield
- JAGX N/A
- MYNZ N/A
- EPS Growth
- JAGX N/A
- MYNZ N/A
- EPS
- JAGX N/A
- MYNZ N/A
- Revenue
- JAGX $10,480,000.00
- MYNZ $917,203.00
- Revenue This Year
- JAGX $32.33
- MYNZ $36.69
- Revenue Next Year
- JAGX $43.63
- MYNZ $91.67
- P/E Ratio
- JAGX N/A
- MYNZ N/A
- Revenue Growth
- JAGX N/A
- MYNZ 16.23
- 52 Week Low
- JAGX $0.84
- MYNZ $0.18
- 52 Week High
- JAGX $21.60
- MYNZ $7.95
- Technical
- Relative Strength Index (RSI)
- JAGX 40.81
- MYNZ 53.35
- Support Level
- JAGX $0.84
- MYNZ $4.30
- Resistance Level
- JAGX $1.29
- MYNZ $7.95
- Average True Range (ATR)
- JAGX 0.09
- MYNZ 0.91
- MACD
- JAGX -0.01
- MYNZ -0.15
- Stochastic Oscillator
- JAGX 3.59
- MYNZ 46.33
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.